10-Q 1 afib-20230331.htm 10-Q afib-20230331
falseQ100015228602023December 31P2YP3Y00015228602023-01-012023-03-3100015228602023-05-08xbrli:shares00015228602023-03-31iso4217:USD00015228602022-12-31iso4217:USDxbrli:shares00015228602022-01-012022-03-310001522860us-gaap:PreferredStockMember2022-12-310001522860us-gaap:CommonStockMember2022-12-310001522860us-gaap:AdditionalPaidInCapitalMember2022-12-310001522860us-gaap:RetainedEarningsMember2022-12-310001522860us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001522860us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001522860us-gaap:CommonStockMember2023-01-012023-03-310001522860us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001522860us-gaap:RetainedEarningsMember2023-01-012023-03-310001522860us-gaap:PreferredStockMember2023-03-310001522860us-gaap:CommonStockMember2023-03-310001522860us-gaap:AdditionalPaidInCapitalMember2023-03-310001522860us-gaap:RetainedEarningsMember2023-03-310001522860us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001522860us-gaap:PreferredStockMember2021-12-310001522860us-gaap:CommonStockMember2021-12-310001522860us-gaap:AdditionalPaidInCapitalMember2021-12-310001522860us-gaap:RetainedEarningsMember2021-12-310001522860us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100015228602021-12-310001522860us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001522860us-gaap:CommonStockMember2022-01-012022-03-310001522860us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001522860us-gaap:RetainedEarningsMember2022-01-012022-03-310001522860us-gaap:PreferredStockMember2022-03-310001522860us-gaap:CommonStockMember2022-03-310001522860us-gaap:AdditionalPaidInCapitalMember2022-03-310001522860us-gaap:RetainedEarningsMember2022-03-310001522860us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100015228602022-03-310001522860us-gaap:IPOMember2020-08-102020-08-100001522860afib:PublicStockOfferingMember2021-07-012021-07-310001522860us-gaap:OverAllotmentOptionMember2021-07-012021-07-310001522860afib:PublicStockOfferingMember2021-07-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMember2022-06-302022-06-300001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMember2022-06-300001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMember2022-11-012022-11-300001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMember2023-01-132023-01-130001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMemberafib:DisposalGroupConsiderationProductSalesPeriodOneMember2023-02-01xbrli:pure0001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMemberafib:DisposalGroupConsiderationProductSalesPeriodTwoMember2023-02-010001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMemberafib:DisposalGroupConsiderationProductSalesPeriodThreeMember2023-02-010001522860afib:DisposalGroupConsiderationProductSalesPeriodFourMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMember2023-02-010001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMember2023-02-012023-02-010001522860afib:LeftHeartAccessPortfolioMember2023-01-012023-03-31afib:segment0001522860srt:MinimumMemberafib:DeferredEquipmentAgreementsMember2023-01-012023-03-310001522860srt:MaximumMemberafib:DeferredEquipmentAgreementsMember2023-01-012023-03-310001522860srt:MinimumMember2023-01-012023-03-310001522860srt:MaximumMember2023-01-012023-03-310001522860srt:MaximumMember2023-03-310001522860afib:DisposablesMember2023-01-012023-03-310001522860afib:DisposablesMember2022-01-012022-03-310001522860afib:SystemsMember2023-01-012023-03-310001522860afib:SystemsMember2022-01-012022-03-310001522860us-gaap:ProductAndServiceOtherMember2023-01-012023-03-310001522860us-gaap:ProductAndServiceOtherMember2022-01-012022-03-310001522860country:US2023-01-012023-03-310001522860country:US2022-01-012022-03-310001522860us-gaap:NonUsMember2023-01-012023-03-310001522860us-gaap:NonUsMember2022-01-012022-03-310001522860us-gaap:TradeAccountsReceivableMember2023-03-310001522860us-gaap:TradeAccountsReceivableMember2022-12-310001522860afib:TransferEarnoutReceivableMember2023-03-310001522860afib:TransferEarnoutReceivableMember2022-12-310001522860afib:CoronavirusAidReliefAndEconomicSecurityActMember2023-03-310001522860afib:CoronavirusAidReliefAndEconomicSecurityActMembersrt:ScenarioForecastMember2023-12-31afib:reporting_unit0001522860us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-03-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-03-310001522860us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-03-310001522860us-gaap:MoneyMarketFundsMember2023-03-310001522860us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2023-03-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-03-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2023-03-310001522860us-gaap:USTreasurySecuritiesMember2023-03-310001522860us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2023-03-310001522860us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2023-03-310001522860us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2023-03-310001522860us-gaap:CommercialPaperMember2023-03-310001522860us-gaap:FairValueInputsLevel1Memberafib:YankeeDebtSecuritiesMember2023-03-310001522860us-gaap:FairValueInputsLevel2Memberafib:YankeeDebtSecuritiesMember2023-03-310001522860us-gaap:FairValueInputsLevel3Memberafib:YankeeDebtSecuritiesMember2023-03-310001522860afib:YankeeDebtSecuritiesMember2023-03-310001522860us-gaap:FairValueInputsLevel1Member2023-03-310001522860us-gaap:FairValueInputsLevel2Member2023-03-310001522860us-gaap:FairValueInputsLevel3Member2023-03-310001522860us-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Member2023-03-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:WarrantMember2023-03-310001522860us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2023-03-310001522860us-gaap:WarrantMember2023-03-310001522860afib:ContingentConsiderationMemberus-gaap:FairValueInputsLevel1Member2023-03-310001522860afib:ContingentConsiderationMemberus-gaap:FairValueInputsLevel2Member2023-03-310001522860afib:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2023-03-310001522860afib:ContingentConsiderationMember2023-03-310001522860us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-12-310001522860us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001522860us-gaap:MoneyMarketFundsMember2022-12-310001522860us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2022-12-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2022-12-310001522860us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2022-12-310001522860us-gaap:USTreasurySecuritiesMember2022-12-310001522860us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2022-12-310001522860us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2022-12-310001522860us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2022-12-310001522860us-gaap:CommercialPaperMember2022-12-310001522860us-gaap:FairValueInputsLevel1Memberafib:YankeeDebtSecuritiesMember2022-12-310001522860us-gaap:FairValueInputsLevel2Memberafib:YankeeDebtSecuritiesMember2022-12-310001522860us-gaap:FairValueInputsLevel3Memberafib:YankeeDebtSecuritiesMember2022-12-310001522860afib:YankeeDebtSecuritiesMember2022-12-310001522860us-gaap:FairValueInputsLevel1Member2022-12-310001522860us-gaap:FairValueInputsLevel2Member2022-12-310001522860us-gaap:FairValueInputsLevel3Member2022-12-310001522860us-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Member2022-12-310001522860us-gaap:FairValueInputsLevel2Memberus-gaap:WarrantMember2022-12-310001522860us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2022-12-310001522860us-gaap:WarrantMember2022-12-310001522860afib:ContingentConsiderationMemberus-gaap:FairValueInputsLevel1Member2022-12-310001522860afib:ContingentConsiderationMemberus-gaap:FairValueInputsLevel2Member2022-12-310001522860afib:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001522860afib:ContingentConsiderationMember2022-12-310001522860afib:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-03-310001522860us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-03-310001522860us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueInputsLevel3Memberafib:RhythmXienceMember2023-03-310001522860us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueInputsLevel3Memberafib:RhythmXienceMember2022-12-310001522860us-gaap:MeasurementInputMaturityMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberafib:RhythmXienceMember2023-03-31afib:year0001522860srt:MaximumMemberus-gaap:MeasurementInputMaturityMemberus-gaap:FairValueInputsLevel3Memberafib:RhythmXienceMember2023-03-310001522860us-gaap:MeasurementInputMaturityMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberafib:RhythmXienceMember2022-12-310001522860srt:MaximumMemberus-gaap:MeasurementInputMaturityMemberus-gaap:FairValueInputsLevel3Memberafib:RhythmXienceMember2022-12-310001522860us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:FairValueInputsLevel3Memberafib:RhythmXienceMember2023-03-310001522860us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:FairValueInputsLevel3Memberafib:RhythmXienceMember2022-12-310001522860us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2023-03-310001522860us-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueInputsLevel3Member2023-03-310001522860us-gaap:WarrantMemberus-gaap:MeasurementInputMaturityMemberus-gaap:FairValueInputsLevel3Member2023-03-310001522860us-gaap:WarrantMemberus-gaap:MeasurementInputPriceVolatilityMemberus-gaap:FairValueInputsLevel3Member2023-03-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMembersrt:ScenarioForecastMemberafib:LeftHeartAccessPortfolioMemberafib:DisposalGroupConsiderationProductSalesPeriodOneMember2023-12-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMembersrt:ScenarioForecastMemberafib:LeftHeartAccessPortfolioMemberafib:DisposalGroupConsiderationProductSalesPeriodTwoMember2023-12-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMembersrt:ScenarioForecastMemberafib:LeftHeartAccessPortfolioMemberafib:DisposalGroupConsiderationProductSalesPeriodThreeMember2023-12-310001522860afib:DisposalGroupConsiderationProductSalesPeriodFourMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMembersrt:ScenarioForecastMemberafib:LeftHeartAccessPortfolioMember2023-12-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMembersrt:ScenarioForecastMemberafib:LeftHeartAccessPortfolioMember2023-01-012023-12-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMember2022-11-300001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMember2023-01-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:LeftHeartAccessPortfolioMember2023-01-012023-03-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:MedtronicMemberafib:LeftHeartAccessPortfolioMember2022-01-012022-12-310001522860us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberafib:MedtronicMemberafib:LeftHeartAccessPortfolioMember2023-01-012023-03-310001522860us-gaap:USTreasurySecuritiesMember2023-03-310001522860us-gaap:CommercialPaperMember2023-03-310001522860afib:YankeeDebtSecuritiesMember2023-03-310001522860us-gaap:USTreasurySecuritiesMember2022-12-310001522860us-gaap:CommercialPaperMember2022-12-310001522860afib:YankeeDebtSecuritiesMember2022-12-310001522860us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-03-310001522860us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-12-310001522860us-gaap:OtherNoncurrentAssetsMember2023-03-310001522860us-gaap:OtherNoncurrentAssetsMember2022-12-310001522860us-gaap:EquipmentMember2023-03-310001522860us-gaap:EquipmentMember2022-12-310001522860us-gaap:FurnitureAndFixturesMember2023-03-310001522860us-gaap:FurnitureAndFixturesMember2022-12-310001522860us-gaap:OfficeEquipmentMember2023-03-310001522860us-gaap:OfficeEquipmentMember2022-12-310001522860afib:LaboratoryEquipmentAndSoftwareMember2023-03-310001522860afib:LaboratoryEquipmentAndSoftwareMember2022-12-310001522860us-gaap:LeaseholdImprovementsMember2023-03-310001522860us-gaap:LeaseholdImprovementsMember2022-12-310001522860us-gaap:ConstructionInProgressMember2023-03-310001522860us-gaap:ConstructionInProgressMember2022-12-310001522860us-gaap:LicensingAgreementsMember2023-01-012023-03-310001522860us-gaap:LicensingAgreementsMember2023-03-310001522860us-gaap:LicensingAgreementsMember2022-01-012022-12-310001522860us-gaap:LicensingAgreementsMember2022-12-310001522860afib:TwoThousandAndTwentyTwoAmendedCreditAgreementMember2023-03-310001522860afib:TwoThousandAndTwentyTwoAmendedCreditAgreementMember2022-12-310001522860afib:SeniorTermLoanMemberafib:TwoThousandAndTwentyTwoAmendedCreditAgreementMember2023-03-310001522860afib:SeniorTermLoanMemberafib:TwoThousandAndTwentyTwoAmendedCreditAgreementMember2022-06-300001522860afib:SeniorTermLoanMemberafib:TwoThousandAndTwentyTwoAmendedCreditAgreementMember2022-06-302022-06-300001522860afib:SeniorTermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberafib:TwoThousandAndTwentyTwoAmendedCreditAgreementMember2022-06-302022-06-300001522860afib:DebtInstrumentAmortizationPaymentPeriodOneMemberafib:SeniorTermLoanMemberafib:TwoThousandAndTwentyTwoAmendedCreditAgreementMember2022-06-302022-06-300001522860afib:DebtInstrumentAmortizationPaymentPeriodTwoMemberafib:SeniorTermLoanMemberafib:TwoThousandAndTwentyTwoAmendedCreditAgreementMember2022-06-302022-06-300001522860afib:DebtInstrumentAmortizationPaymentPeriodThreeMemberafib:SeniorTermLoanMemberafib:TwoThousandAndTwentyTwoAmendedCreditAgreementMember2022-06-302022-06-300001522860us-gaap:WarrantMember2022-06-300001522860us-gaap:WarrantMember2022-06-302022-06-300001522860afib:CorporateOfficeSpaceAndManufacturingFacilityMember2023-03-31utr:sqft0001522860afib:OfficeSpaceZaventemBelgiumMember2023-03-3100015228602022-02-14afib:lawsuit0001522860afib:WarrantsIssuedInTwoThousandAndFifteenMemberus-gaap:CommonStockMember2023-03-310001522860afib:WarrantsIssuedInTwoThousandAndFifteenMemberus-gaap:CommonStockMember2022-12-310001522860afib:WarrantsIssuedInTwoThousandAndEighteenWithConvertibleNotesMemberus-gaap:CommonStockMember2023-03-310001522860afib:WarrantsIssuedInTwoThousandAndEighteenWithConvertibleNotesMemberus-gaap:CommonStockMember2022-12-310001522860afib:WarrantsIssuedInTwoThousandAndEighteenTermLoanMemberus-gaap:CommonStockMember2023-03-310001522860afib:WarrantsIssuedInTwoThousandAndEighteenTermLoanMemberus-gaap:CommonStockMember2022-12-310001522860afib:WarrantsIssuedInTwoThousandAndNineteenCreditAgreementMemberus-gaap:CommonStockMember2023-03-310001522860afib:WarrantsIssuedInTwoThousandAndNineteenCreditAgreementMemberus-gaap:CommonStockMember2022-12-310001522860us-gaap:CommonStockMemberafib:WarrantsIssuedInTwoThousandAndTwentyTwoAmendedCreditAgreementMember2023-03-310001522860us-gaap:CommonStockMemberafib:WarrantsIssuedInTwoThousandAndTwentyTwoAmendedCreditAgreementMember2022-12-31afib:holder00015228602021-08-012021-08-31afib:investor0001522860us-gaap:CommonStockMember2021-08-012021-08-310001522860us-gaap:SeriesAPreferredStockMember2021-08-012021-08-310001522860us-gaap:SeriesAPreferredStockMember2021-08-310001522860us-gaap:SeriesAPreferredStockMember2023-03-310001522860us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001522860us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001522860afib:TwoThousandTwentyTwoInducementEquityIncentivePlanMember2023-03-310001522860afib:TwoThousandTwentyEquityIncentivePlanMember2023-03-310001522860afib:TwoThousandTwentyEquityIncentivePlanMember2023-01-012023-01-010001522860afib:TwoThousandElevenPlanMember2023-03-310001522860afib:TwoThousandElevenPlanMember2023-01-012023-03-3100015228602022-01-012022-12-310001522860us-gaap:RestrictedStockUnitsRSUMember2022-12-310001522860us-gaap:RestrictedStockUnitsRSUMember2023-03-310001522860afib:TwoThousandTwentyEmployeeStockPurchasePlanMember2020-08-050001522860afib:TwoThousandTwentyEmployeeStockPurchasePlanMember2023-03-310001522860srt:MaximumMemberafib:TwoThousandTwentyEmployeeStockPurchasePlanMember2023-01-012023-03-310001522860us-gaap:CostOfSalesMember2023-01-012023-03-310001522860us-gaap:CostOfSalesMember2022-01-012022-03-310001522860us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001522860us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001522860us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001522860us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001522860afib:ConversionOfPreferredConvertiblesSeriesAStockMember2023-01-012023-03-310001522860afib:ConversionOfPreferredConvertiblesSeriesAStockMember2022-01-012022-03-310001522860us-gaap:WarrantMember2023-01-012023-03-310001522860us-gaap:WarrantMember2022-01-012022-03-310001522860us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001522860us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001522860afib:PerformanceShareUnitsAndRestrictedStockUnitsMember2023-01-012023-03-310001522860afib:PerformanceShareUnitsAndRestrictedStockUnitsMember2022-01-012022-03-310001522860afib:IssuanceOfStockESPPMember2023-01-012023-03-310001522860afib:IssuanceOfStockESPPMember2022-01-012022-03-310001522860afib:FourZeroOneKRetirementPlanMember2023-01-012023-03-310001522860afib:FourZeroOneKRetirementPlanMember2022-01-012022-03-310001522860srt:MaximumMemberafib:DirectorAndTheChairmanMemberafib:ConsultingAgreementMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001522860srt:MaximumMemberafib:DirectorAndTheChairmanMemberafib:ConsultingAgreementMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001522860afib:SeniorTermLoanMemberafib:TwoThousandAndNineteenCreditAgreementMember2019-05-200001522860afib:TwoThousandAndNineteenCreditAgreementMember2022-06-300001522860afib:TwoThousandAndNineteenCreditAgreementMember2022-12-310001522860afib:TwoThousandAndNineteenCreditAgreementMember2021-12-310001522860afib:OrbimedRoyaltyOppurtunitiesTwoLpAndDeerfieldPrivateDesignFundLpMemberafib:TwoThousandAndNineteenCreditAgreementMember2022-01-012022-12-310001522860afib:OrbimedRoyaltyOppurtunitiesTwoLpAndDeerfieldPrivateDesignFundLpMemberafib:TwoThousandAndNineteenCreditAgreementMember2021-01-012021-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 10-Q
__________________________________
(Mark one)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number 001-39430
__________________________________
gbk0ijuxhbuw000001.jpg
ACUTUS MEDICAL, INC.
(Exact name of registrant as specified in its charter)
__________________________________
Delaware45-1306615
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
2210 Faraday Ave.,
Suite 100, Carlsbad, CA
92008
(Address of principal executive offices)(Zip Code)
(Registrant’s telephone number, including area code) (442) 232-6080
___________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol		Name of each exchange on which registered 
Common Stock, par value $0.001 per shareAFIBThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  ☐    No  ☒
Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.
Class of Common StockOutstanding Shares as of May 8, 2023
Common Stock, $0.001 par value28,975,677

Acutus Medical, Inc.
Form 10-Q
For the Quarter Ended March 31, 2023
Table of Contents
Page


Item 1. Financial Statements.
Acutus Medical, Inc.
Condensed Consolidated Balance Sheets
March 31,
2023		December 31,
2022
(in thousands, except share and per share amounts)(unaudited)
ASSETS
Current assets:
Cash and cash equivalents$22,738 $25,584 
Marketable securities, short-term46,839 44,863 
Restricted cash, short-term7,139 5,764 
Accounts receivable5,340 21,085 
Inventory14,938 13,327 
Employer retention credit receivable2,562 4,703 
Prepaid expenses and other current assets2,232 2,541 
Total current assets101,788 117,867 
Property and equipment, net8,145 9,221 
Right-of-use assets, net3,708 3,872 
Intangible assets, net1,533 1,583 
Other assets822 897 
Total assets$115,996 $133,440 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$5,569 $4,721 
Accrued liabilities7,302 9,686 
Contingent consideration, short-term2,000 1,800 
Operating lease liabilities, short-term339 319 
Warrant liability1,900 3,346 
Total current liabilities17,110 19,872 
Operating lease liabilities, long-term3,883 4,103 
Long-term debt34,526 34,434 
Other long-term liabilities11 12 
Total liabilities55,530 58,421 
Commitments and contingencies (Note 12)
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 6,666 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of March 31, 2023 and December 31, 2022
— — 
Common stock, $0.001 par value; 260,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 28,894,080 and 28,554,656 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively
29 29 
Additional paid-in capital595,864 594,173 
Accumulated deficit(534,629)(518,314)
Accumulated other comprehensive loss(798)(869)
Total stockholders' equity60,466 75,019 
Total liabilities and stockholders' equity$115,996 $133,440 
The accompanying notes are an integral part of these condensed consolidated financial statements.
1
Acutus Medical, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
Three Months Ended March 31,
20232022
(in thousands, except share and per share amounts)(unaudited)
Revenue$4,170 $3,681 
Cost of products sold6,790 6,941 
Gross profit(2,620)(3,260)
Operating (income) expenses:
Research and development6,117 8,003 
Selling, general and administrative9,565 14,385 
Goodwill impairment— 12,026 
Restructuring12 949 
Change in fair value of contingent consideration200 7 
Gain on sale of business(1,207)— 
Total operating (income) expenses14,687 35,370 
Loss from operations(17,307)(38,630)
Other income (expense):
Change in fair value of warrant liability1,446 — 
Interest income853 24 
Interest expense(1,307)(1,411)
Total other income (expense), net992 (1,387)
Loss before income taxes(16,315)(40,017)
Income tax benefit— — 
Net loss$(16,315)$(40,017)
Other comprehensive income (loss)
Unrealized gain (loss) on marketable securities12 (57)
Foreign currency translation adjustment59 (166)
Comprehensive loss$(16,244)$(40,240)
Net loss per common share, basic and diluted$(0.57)$(1.42)
Weighted average shares outstanding, basic and diluted28,764,444 28,118,090 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
Acutus Medical, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
For the Three Months Ended March 31, 2023
(in thousands, except share amounts)Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Accumulated
Other
Comprehensive
Income (Loss)		Total
Stockholders'
Equity
SharesAmountSharesAmount
Balance as of December 31, 20226,666 $— 28,554,656 $29 $594,173 $(518,314)$(869)$75,019 
Unrealized gain on marketable securities— — — — — — 12 12 
Foreign currency translation adjustment— — — — — — 59 59 
Stock option exercises— — 3,218 — 4 — — 4 
Stock-based compensation— — 336,206 — 1,687 — — 1,687 
Net loss— — — — — (16,315)— (16,315)
Balance as of March 31, 2023 (unaudited)6,666 $— 28,894,080 $29 $595,864 $(534,629)$(798)$60,466 
For the Three Months Ended March 31, 2022
(in thousands, except share amounts)Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Accumulated
Other
Comprehensive
Loss		Total
Stockholders'
Equity
SharesAmountSharesAmount
Balance as of December 31, 20216,666 $— 27,957,223 $28 $584,613 $(478,698)$(217)$105,726 
Unrealized loss on marketable securities— — — — — — (57)(57)
Foreign currency translation adjustment— — — — — — (166)(166)
Stock option exercises— — 35,478 — 66 — — 66 
Stock-based compensation— — 192,138 — 3,028 — — 3,028 
Employee stock purchase plan shares issued— — 94,226 — 182 — — 182 
Net loss— — — — — (40,017)— (40,017)
Balance as of March 31, 2022 (unaudited)6,666 $— 28,279,065 $28 $587,889 $(518,715)$(440)$68,762 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
Acutus Medical, Inc.
Condensed Consolidated Statements of Cash Flows
Three Months Ended March 31,
20232022
(in thousands)(unaudited)
Cash flows from operating activities
Net loss$(16,315)$(40,017)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense1,297 1,567 
Amortization of intangible assets50 160 
Non-cash stock-based compensation expense1,904 3,032 
(Accretion of discounts) amortization of premiums on marketable securities, net(527)173 
Amortization of debt issuance costs104 378 
Amortization of operating lease right-of-use assets164 160 
Goodwill impairment— 12,026 
Gain on sale of business, net(1,207)— 
Change in fair value of warrant liability(1,446)— 
Loss on disposal of property and equipment38 — 
Change in fair value of contingent consideration200 7 
Changes in operating assets and liabilities:
Accounts receivable(11)655 
Inventory(1,611)(1,212)
Employer retention credit receivable2,141 — 
Prepaid expenses and other current assets391 (3,487)
Other assets75 120 
Accounts payable873 (2,641)
Accrued liabilities(2,433)1,532 
Operating lease liabilities(201)(14)
Other long-term liabilities(1)(48)
Net cash used in operating activities(16,515)(27,609)
Cash flows from investing activities
Proceeds from sale of business17,000 — 
Purchases of available-for-sale marketable securities(28,019)— 
Sales of available-for-sale marketable securities— 2,500 
Maturities of available-for-sale marketable securities26,500 14,587 
Purchases of property and equipment(232)(1,088)
Net cash provided by investing activities15,249 15,999 
Cash flows from financing activities
Proceeds from the exercise of stock options4 66 
Repurchase of common shares to pay employee withholding taxes(217)— 
Proceeds from employee stock purchase plan— 182 
Payment of contingent consideration— (290)
Net cash used in financing activities(213)(42)
Effect of exchange rate changes on cash, cash equivalents and restricted cash8 (100)
Net change in cash, cash equivalents and restricted cash(1,471)(11,752)
Cash, cash equivalents and restricted cash, at the beginning of the period31,348 24,221 
Cash, cash equivalents and restricted cash, at the end of the period$29,877 $12,469 
Supplemental disclosure of cash flow information:
Cash paid for interest$1,207 $1,025 
Supplemental disclosure of noncash investing and financing activities:
Accounts receivable from sale of business$1,244 $— 
Change in unrealized (gain) loss on marketable securities$(12)$57 
Change in unpaid purchases of property and equipment$(25)$(97)
Contingent consideration escrow release$— $17 
4
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
Acutus Medical, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1—Organization and Description of Business
Acutus Medical, Inc. (the “Company”) is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The Company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. The Company’s product portfolio includes novel access sheaths, diagnostic and mapping catheters, ablation catheters, mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The Company was incorporated in the state of Delaware on March 25, 2011, and is located in Carlsbad, California.
Liquidity, Capital Resources and Going Concern
The Company has limited revenue, has incurred significant operating losses and negative cash flows from operations since its inception, and anticipates that it will incur significant losses for at least the next several years. As of March 31, 2023 and December 31, 2022, the Company had cash, cash equivalents, restricted cash and marketable securities of $76.7 million and $76.2 million, respectively. For the three months ended March 31, 2023 and 2022, net losses were $16.3 million and $40.0 million, respectively, and net cash used in operating activities was $16.5 million and $27.6 million, respectively. As of March 31, 2023 and December 31, 2022, the Company had an accumulated deficit of $534.6 million and $518.3 million, respectively, and working capital of $84.7 million and $98.0 million, respectively.

Since raising $166.3 million from its IPO in August 2020, the Company has issued additional shares of common stock. From time to time, the Company's Board of Directors issues common stock for its stock-based compensation plans and for its ESPP. Additionally, in July 2021, the Company issued 6,325,000 shares of common stock in a public offering, which included 825,000 shares of common stock issued upon the underwriter’s exercise in full of an option to purchase additional shares of common stock. The price to the public for each share was $14.00. The Company received gross proceeds of $88.6 million from the offering. Net of underwriting discounts and commission and other offering expenses, the Company received proceeds of $82.7 million.

On June 30, 2022, Medtronic, Inc. (“Medtronic”) paid the Company $50.0 million at the first closing (the "First Closing") of the sale of the Company's left-heart access portfolio to Medtronic, of which $4.0 million was paid into an indemnity escrow account for a period of 18 months following the First Closing to secure the Company's indemnification obligations under the asset purchase agreement ("Asset Purchase Agreement") entered into with Medtronic on April 26, 2022. The OEM Earnout (as defined in Note 3 - Sale of Business, below) under the Asset Purchase Agreement with Medtronic was achieved on October 31, 2022, with $20.0 million paid by Medtronic to the Company in November 2022. Additionally, the Transfer Earnout (as defined in Note 3 - Sale of Business, below) under the Asset Purchase Agreement with Medtronic was achieved on December 21, 2022, with $17.0 million paid by Medtronic to the Company in January 2023. Beginning in February 2023, following Medtronic's first commercial sale of the left-heart access products after the Company's achievement of the OEM Earnout (as defined in Note 3 - Sale of Business, below), the Company became eligible to earn amounts equal to 100%, 75%, 50% and 50%, respectively, of quarterly Net Sales (as defined in the Asset Purchase Agreement) from sales of the left-heart access products achieved by Medtronic each year over four years. During the three months ended March 31, 2023, the Company earned $1.2 million in contingent consideration based on Medtronic's left-heart access products sales.

Management believes the Company’s current cash, cash equivalents and marketable securities are sufficient to fund operations for at least the next 12 months from the date of this filing. To ensure that the Company has sufficient resources to fund operations, management continues to review cost improvement opportunities and pathways to reduce expenses and cash burn, while preserving the resources to invest in future growth.

In the future, the Company may need to raise additional funds through one or more of the following: the issuance of debt and/or equity securities or otherwise. Until such time, if ever, that the Company can generate revenue sufficient to achieve profitability, the Company expects to finance its operations through equity or debt financings, which may not be available to the Company on the timing needed or on terms that the Company deems to be favorable. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If the Company is unable to maintain sufficient financial resources, its business, financial condition, and results of operations will be materially and adversely affected. The Company may be required to delay, limit, reduce or terminate its product discovery and development activities or future commercialization efforts.
6
Note 2—Summary of Significant Accounting Policies
Basis of Presentation
The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and note disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.
Principles of Consolidation
The condensed consolidated financial statements include the accounts of Acutus Medical, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates and Assumptions
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and disclosures of contingent assets and liabilities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates.
Segments
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment and reportable segment.
Cash and Cash Equivalents and Restricted Cash
The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. All of the Company’s cash equivalents have liquid markets and high credit ratings. The Company maintains its cash in bank deposits and other accounts, the balances of which, at times and as of March 31, 2023 and December 31, 2022, exceeded federally insured limits.

Restricted cash consists of (i) deposited cash collateral for the Company’s corporate credit card program and (ii) cash received for the sale of business to Medtronic held in an indemnity escrow account until certain terms of sale are met.
The following table reconciles cash, cash equivalents and restricted cash in the condensed consolidated balance sheets to the total balances as of March 31, 2023 and December 31, 2022 (in thousands):
March 31,
2023		December 31,
2022
(unaudited)
Cash and cash equivalents$22,738 $25,584 
Restricted cash7,139 5,764 
Total cash, cash equivalents and restricted cash$29,877 $31,348 
Marketable Securities
The Company’s marketable securities portfolio consists of investments in money market funds, commercial paper, U.S. treasury securities and Yankee debt securities.
The Company considers its debt securities to be available-for-sale securities. Available-for-sale securities are classified as cash equivalents or short-term or long-term marketable securities based on the maturity date at time of purchase and their availability
7
to meet current operating requirements. Marketable securities that mature in three months or less from the date of purchase are classified as cash equivalents. Marketable securities, excluding cash equivalents, that mature in one year or less are classified as short-term available-for-sale securities and are reported as a component of current assets.
Securities that are classified as available-for-sale are measured at fair value with temporary unrealized gains and losses reported in other comprehensive loss, and as a component of stockholders’ equity until their disposition or maturity. See “Fair Value Measurements” below. The Company reviews all available-for-sale securities at each period end to determine if they remain available-for-sale based on the Company’s current intent and ability to sell the security if it is required to do so. Realized gains and losses from the sale of marketable securities, if any, are calculated using the specific-identification method.
Marketable securities are subject to a periodic impairment review. The Company may recognize an impairment charge when a decline in the fair value of investments below the cost basis is determined to be other-than-temporary. In determining whether a decline in market value is other-than-temporary, various factors are considered, including the cause, duration of time and severity of the impairment, any adverse changes in the investees’ financial condition and the Company’s intent and ability to hold the security for a period of time sufficient to allow for an anticipated recovery in market value. Declines in value judged to be other-than-temporary are included in the Company’s condensed consolidated statements of operations and comprehensive loss. The Company did not record any other-than-temporary impairments related to marketable securities in the Company’s condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023 and 2022.
Concentrations of Credit Risk and Off-Balance Sheet Risk
Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, restricted cash, accounts receivable and marketable securities. Cash and restricted cash are maintained in accounts with financial institutions which, at times, may exceed the federal depository insurance coverage of $0.25 million. The Company has not experienced losses on these accounts, and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.
Revenue from Contracts with Customers
The Company accounts for revenue earned from contracts with customers under Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers (“ASC 606”), and ASC 842, Leases ("ASC 842"). The core principle of ASC 606 is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:
•Step 1: Identify the contract with the customer.
•Step 2: Identify the performance obligations in the contract.
•Step 3: Determine the transaction price.
•Step 4: Allocate the transaction price to the performance obligations in the contract.
•Step 5: Recognize revenue when, or as, the company satisfies a performance obligation.

ASC 842 provides guidance on determining whether an agreement contains a lease. ASC 842 defines a lease as a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration.

For new customers, the Company places its medical diagnostic equipment, the AcQMap System, at customer sites under evaluation agreements and generates revenue from the sale of disposable products used with the AcQMap System. Disposable products primarily include AcQMap catheters and AcQGuide steerable sheaths. Outside of the United States, the Company also has the Qubic Force Device which generates revenue from the sale of the AcQBlate Force Ablation Catheters. The Company provides the disposable products in exchange for consideration, which occurs when a customer submits a purchase order and the Company provides disposables at the agreed upon prices in the invoice. Generally, customers purchase disposable products using separate purchase orders after the equipment has been provided to the customer for free with no binding agreement or requirement to purchase any disposable products. The Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to fulfill the promise to transfer the disposable products and not as a separate performance obligation.

Additionally, the Company sells the AcQMap System to customers along with software updates on a when-and-if-available basis, as well as the Qubic Force Device and a transseptal crossing line of products which can be used in a variety of heart procedures and does not need to be accompanied with an AcQMap System or Qubic Force Device. Included in the transseptal
8
crossing line of products are primarily the AcQRef Introducer Sheath, the AcQGuide Sheaths and the AcQCross Transseptal Dilator/Needle.

The Company also enters into deferred equipment agreements that are generally structured such that the Company agrees to provide an AcQMap System at no up-front charge, with title of the device transferring to the customer at the end of the contract term, in exchange for the customer’s commitment to purchase disposables at a specified price over the term of the agreement, which generally ranges from two to four years. The Company has determined that such deferred equipment agreements include an embedded sales-type lease. The Company allocates contract consideration under deferred equipment agreements containing fixed annual disposable purchase commitments to the underlying lease and non-lease components at contract inception. The Company expenses the cost of the device at the inception of the agreement and records a financial lease asset equal to the gross consideration allocated to the lease. The lease asset is reduced by payments for minimum disposable purchases that are allocated to the lease.

Lastly, the Company enters into short-term operating leases for the rental of the AcQMap System after an evaluation. These lease agreements impose no requirement on the customer to purchase the equipment, and the equipment is not transferred to the customer at the end of the lease term. The short-term nature of the lease agreements does not result in lease payments accumulating to an amount that equals the value of the equipment nor is the lease term reflective of the economic life of the equipment.
The Company’s contracts primarily include fixed consideration. Generally, there are no discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 to 60 days.
The delivery of disposable products are performance obligations satisfied at a point in time. The disposable products are shipped Free on Board (“FOB”) shipping point or FOB destination. For disposable products that are shipped FOB shipping point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave the Company’s shipping facilities, and thus the customer obtains control and revenue is recognized at that point in time. Revenue is recognized on delivery for disposable products shipped via FOB destination.

For direct customers, the installation and delivery of the AcQMap System is satisfied at a point in time when the installation is complete, which is when the customer can benefit and has control of the system. For AcQMap System sales sold to Biotronik SE & Co. KG (“Biotronik”), the installation is not a performance obligation as it is performed by Biotronik, and therefore the AcQMap System is satisfied at a point in time when they have control of the system. The Company’s software updates and equipment service performance obligations are satisfied evenly over time as the customer simultaneously receives and consumes the benefits of the Company’s performance for these services throughout the service period.

The Company allocates the transaction price to each performance obligation identified in the contract based on the relative standalone selling price (“SSP”). The Company determines SSP for the purposes of allocating the transaction price to each performance obligation based on the adjusted market assessment approach that maximizes the use of observable inputs, which include, but are not limited to, sales transactions where the specific performance obligations are sold separately, Company list prices and specific offers to customers.
Except for the deferred equipment agreements noted above, the Company’s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to obtain contracts are recorded as selling, general and administrative ("SG&A") expense as incurred due to the short duration of the Company’s contracts. The Company’s contract balances consisted solely of accounts receivable as of March 31, 2023 and December 31, 2022.

In May 2020, the Company entered into bi-lateral distribution agreements (the “Bi-Lateral Distribution Agreements”) with Biotronik. Pursuant to the Bi-Lateral Distribution Agreements, the Company obtained a non-exclusive license to distribute a range of Biotronik’s products and accessories in the United States, Canada, China, Hong Kong and multiple Western European countries under the Company’s private label. Moreover, if an investigational device exemption (“IDE”) clinical trial is required for these products to obtain regulatory approval in the United States, or a clinical trial is required for these products to obtain regulatory approval in China, the Company will obtain an exclusive distribution right in such territories for a term of up to five years commencing on the date of regulatory approval if the Company covers the cost of the IDE or other clinical trial and the Company conducts such study within a specified period. Biotronik also agreed to distribute the Company’s products and accessories in Germany, Japan, Mexico, Switzerland and multiple countries in Asia-Pacific, Eastern Europe, the Middle East and South America. The Company also granted Biotronik a co-exclusive right to distribute these products in Hong Kong. Each party will pay to the other party a specified transfer price on the sale of the other party’s products and, accordingly, will earn a distribution margin on the sale of the other party’s products.

9
In 2022, the Company sold the left-heart access transseptal crossing business to Medtronic. In connection with the sale, the Company entered into a distribution agreement (the "Distribution Agreement") with Medtronic, pursuant to which the Company acts as the original equipment manufacturer ("OEM") supplier of these products. The Company will produce and sell the products to Medtronic for a period of up to four years. Revenue is recognized when the title to the products are transferred to Medtronic, which occurs when the products are shipped from our facility (or FOB shipping point).
The following table sets forth the Company’s revenue for disposables, systems and service/other for the three months ended March 31, 2023 and 2022 (in thousands):
Three Months Ended March 31,
20232022
(unaudited)
Disposables$3,426 $3,211 
Systems— — 
Service/Other744 470 
Total revenue$4,170 $3,681 
The following table provides revenue by geographic location for the three months ended March 31, 2023 and 2022 (in thousands):
Three Months Ended March 31,
20232022
(unaudited)
United States$2,248 $2,023 
Outside the United States1,922 1,658 
Total revenue$4,170 $3,681 
Inventory
Inventory is stated at the lower of cost (first-in, first-out basis) or net realizable value. The Company recorded write-downs for excess and obsolete inventory of $0.3 million and $1.0 million for the three months ended March 31, 2023 and 2022, respectively, based on management’s review of inventories on hand, comparisons to estimated future usage and sales, observed shelf-life and assumptions about the likelihood of obsolescence.

Accounts Receivable
Trade accounts receivable are recorded net of allowances for uncollectible accounts. The Company evaluates the collectability of its accounts receivable based on various factors including historical experience, the length of time the receivables are past due and the financial health of the customer. The Company reserves specific receivables if collectability is no longer reasonably assured. Based upon the assessment of these factors, the Company did not record an allowance for uncollectible accounts as of March 31, 2023 or December 31, 2022.

Pursuant to the Asset Purchase Agreement with Medtronic, the Company was eligible to receive the Transfer Earnout, a contingent cash consideration of $17.0 million upon the Company’s initial submission for CE Mark certification. The Company met this condition as of December 31, 2022 and recorded a receivable on the consolidated balance sheets for the year then ended. Medtronic provided full payment in January 2023. See Note 3 - Sale of Business.

In addition, beginning in February 2023, following Medtronic's first commercial sale of the left-heart access products after the Company's achievement of the OEM Earnout (as defined in Note 3 - Sale of Business, below), the Company became eligible to earn amounts equal to 100%, 75%, 50% and 50%, respectively, of quarterly Net Sales (as defined in the Asset Purchase Agreement) from sales of the left-heart access products achieved by Medtronic each year over four years. During the three months ended March 31, 2023, the Company earned $1.2 million in contingent consideration based on Medtronic's left-heart access products sales and recorded a receivable on the condensed consolidated balance sheets for the period then ended.

Accounts receivable recorded on the condensed consolidated balance sheets as of March 31, 2023 and December 31, 2022 consists of the following (in thousands):

10
March 31,
2023		December 31,
2022
(unaudited)
Trade accounts receivable$4,096 $4,085 
Earnouts receivable from Medtronic1,244 17,000 
Total accounts receivable$5,340 $21,085 

Employee Retention Credit Receivable
The Employee Retention Credit is a refundable U.S. tax credit separate from tax based on income for businesses that continued to pay employees while shut down due to the COVID-19 pandemic or had significant declines in gross receipts from March 13, 2020 to December 31, 2021. The Company is an eligible employer qualifying under the program and applied for the tax credit in 2022. As of March 31, 2023, $4.2 million has been refunded to the Company, of which $2.1 million was received during the three months ended March 31, 2023. The Company expects receipt of the remaining $2.6 million receivable in 2023.
Property and Equipment, Net
Property and equipment are recorded at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets, generally three to five years, or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term.
Intangible Assets
The Company’s intangible assets consists of a license agreement with Biotronik. The Company determines the appropriate useful life of its finite-lived intangible assets by performing an analysis of expected cash flows of the acquired assets. Finite-lived intangible assets are amortized over their estimated useful lives using the straight-line method, which approximates the pattern in which the economic benefits are consumed. Acquired in-process technology is classified as a finite-lived intangible and amortized accordingly. Indefinite-lived intangible assets are tested for impairment at least annually and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Indefinite-lived intangible assets are impaired if their estimated fair values are less than their carrying value.
Goodwill
Goodwill represents the excess of the purchase price of an entity over the estimated fair value of the assets acquired and liabilities assumed, and it is presented as goodwill in the accompanying condensed consolidated balance sheets. Under ASC 350, Intangibles – Goodwill and Other (“ASC 350”), goodwill is not amortized but is subject to periodic impairment testing. ASC 350 requires that an entity assign its goodwill to reporting units and test each reporting unit’s goodwill for impairment at least on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. In the evaluation of goodwill for impairment, which is performed annually during the fourth quarter, the Company first assesses qualitative factors to determine whether the existence of events or circumstances led to a determination that it was more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events or circumstances, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company is required to perform the quantitative goodwill impairment test. The Company has one reporting unit. During the three months ended March 31, 2022, the Company fully impaired its goodwill balance of $12.0 million.
Impairment of Long-Lived Assets
The Company reviews long-lived assets, including property and equipment and finite-lived intangible assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss is recognized when the asset’s carrying value exceeds the total undiscounted cash flows expected from its use and eventual disposition. The amount of the impairment loss is determined as the excess of the carrying value of the asset over its fair value. For the three months ended March 31, 2023 and 2022, the Company determined that there was no impairment of property and equipment or intangible assets.
Foreign Currency Translation and Transactions
11
The assets, liabilities and results of operations of Acutus Medical N.V. and Acutus Medical UK Limited are measured using their functional currency, the Euro and British Pound Sterling, respectively, which is the currency of the primary foreign economic environment in which the subsidiaries operate. Upon consolidating these entities with the Company, their assets and liabilities are translated to U.S. dollars at currency exchange rates as of the balance sheet date and their revenues and expenses are translated at the weighted average currency exchange rates during the applicable reporting periods. Translation adjustments resulting from the process of translating the entities’ financial statements are reported in accumulated other comprehensive loss in the condensed consolidated balance sheets and foreign currency translation adjustment in the condensed consolidated statements of operations and comprehensive loss.
Lease Property
The Company leases office space in Carlsbad, California as its corporate headquarters and for manufacturing operations. Additionally, it leases office space in Zaventem, Belgium for international operations. The Company accounts for its lease property under ASC 842. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases, and are recorded on the consolidated balance sheet as both a right-of-use asset and a lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate, which is the rate for collateralized borrowings based on the current economic environment, credit history, credit rating, value of leases, currency in which the lease obligation is satisfied, rate sensitivity, lease term and materiality. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset results in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.

In calculating the right-of-use asset and lease liability, the Company elected to combine lease and non-lease components. The Company adopted the policy election to exclude short-term leases having initial terms of twelve months from the initial recognition provisions of ASC 842. See Note 12 - Operating leases for additional details.
Cost of Products Sold
Cost of products sold includes raw materials, direct labor, manufacturing overhead, shipping and receiving costs and other less significant indirect costs related to the production of the Company’s products.
Research and Development
The Company is actively engaged in new product research and development efforts. Research and development expenses consist primarily of salaries and employee-related costs (including stock-based compensation) for personnel directly engaged in research and development activities, clinical trial expenses, equipment costs, material costs, allocated rent and facilities costs and depreciation.
Research and development expenses relating to possible future products are expensed as incurred. The Company also accrues and expenses costs for activities associated with clinical trials performed by third parties as incurred. All other costs relative to setting up clinical trial sites are expensed as incurred. Clinical trial site costs related to patient enrollment are accrued as patients are entered into the trials.
Selling, General and Administrative
SG&A expenses consist primarily of salaries and employee-related costs (including stock-based compensation) for personnel in sales, executive, finance and other administrative functions, allocated rent and facilities costs, legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services, marketing costs and insurance costs. The Company expenses all SG&A costs as incurred.

Fair Value Measurements
Financial Instruments
Fair value measurements are based on the premise that fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy is used in determining the inputs for measuring fair value:
12
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.
Level 3—Unobservable inputs which are supported by little or no market activity and consist of financial instruments valued using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Management’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. There were no transfers made among the three levels in the fair value hierarchy for the three months ended March 31, 2023 and 2022.
As of March 31, 2023 and December 31, 2022, the Company’s cash (excluding cash equivalents which are recorded at fair value on a recurring basis), restricted cash, accounts receivable, accounts payable and accrued expenses were carried at cost, which approximates the fair values due to the short-term nature of each instrument. The carrying amount of the Company’s long-term debt approximates fair value due to its variable market interest rate and management’s opinion that current rates and terms that would be available to the Company with the same maturity and security structure would be essentially equivalent to that of the Company’s long-term debt.
The following tables classify the Company’s financial assets and liabilities measured at fair value on a recurring basis into the fair value hierarchy as of March 31, 2023 and December 31, 2022 (in thousands):

Fair Value Measurements as of March 31, 2023
(unaudited)
Quoted
Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets included in:
Cash and cash equivalents
Money market securities$20,211 $— $— $20,211 
Marketable securities at fair value
U.S. treasury securities— 21,814 — 21,814 
Commercial paper— 21,806 — 21,806 
Yankee debt securities— 3,219 — 3,219 
Total fair value$20,211 $46,839 $— $67,050 
Liabilities included in:
Warrant liability$— $— $1,900 $1,900 
Contingent consideration— — 2,000 2,000 
Total fair value$— $— $3,900 $3,900 

13
Fair Value Measurements as of December 31, 2022
Quoted
Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets included in:
Cash and cash equivalents
Money market securities$22,700 $— $— $22,700 
Marketable securities at fair value
U.S. treasury securities— 26,897 — 26,897 
Commercial paper— 14,764 — 14,764 
Yankee debt securities— 3,202 — 3,202 
Total fair value$22,700 $44,863 $— $67,563 
Liabilities included in:
Warrant liability$— $— $3,346 $3,346 
Contingent consideration— — 1,800 1,800 
Total fair value$— $— $5,146 $5,146 

The fair value of the Company’s money market securities is determined using quoted market prices in active markets for identical assets.

The fair value for the available-for-sale marketable securities is determined based on valuation models using inputs that are observable either directly or indirectly (Level 2 inputs) such as quoted prices for similar assets, yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments, broker and dealer quotes, as well as other relevant economic measures.

Financial Obligations
The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2023 (in thousands):
Contingent
Consideration		Warrant Liability
Balance, December 31, 2022$1,800 $3,346 
Change in fair value200 (1,446)
Balance, March 31, 2023 (unaudited)$2,000 $1,900 
Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs.

Contingent Consideration
The fair value of the contingent consideration from the acquisition of Rhythm Xience, Inc. ("Rhythm Xience") in June 2019 represents the estimated fair value of future payments due to the sellers of Rhythm Xience based on the achievement of certain milestones and revenue-based targets in certain years. The initial fair value of the revenue-based contingent consideration was calculated through the use of a Monte Carlo simulation using revenue projections for the respective earn-out period, corresponding targets and approximate timing of payments as outlined in the purchase agreement. The analyses used the following assumptions: (i) expected term; (ii) risk-adjusted net sales; (iii) risk-free interest rate; and (iv) expected volatility of net sales (see table below). Estimated payments, as determined through the respective model, were further discounted by a credit spread assumption to account for credit risk. The fair value of the milestones-based contingent consideration was determined by probability weighting and discounting to the respective valuation date at the Company’s cost of debt. The Company’s cost of debt was determined by performing a synthetic credit rating for the Company and selecting yields based on
14
companies with a similar credit rating. The contingent consideration is revalued to fair value each period on the condensed consolidated balance sheets, and any increase or decrease is recorded on the condensed consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration may be impacted by certain unobservable inputs, most significantly with regard to discount rates, expected volatility and historical and projected performance. Significant changes to these inputs in isolation could result in a significantly different fair value measurement.

The weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the contingent consideration from the acquisition of Rhythm Xience as of March 31, 2023 and December 31, 2022 were as follows:

March 31, 2023December 31, 2022
(unaudited)
Risk-free interest rate5.00%4.80%
Expected term in years
1.0 - 2.0
1.0 - 2.0
Expected volatility23.4%28.0%

Warrants
As of March 31, 2023, the fair value of the common stock warrants was estimated using the Black-Scholes option pricing model. The fair value was estimated to be $0.5026 per warrant as of March 31, 2023 and the significant inputs used in the estimation of the fair value were as follows:
March 31, 2023
(unaudited)
Risk-free interest rate3.55%
Expected term in years7.25
Expected volatility75.0%

Stock-Based Compensation
The Company accounts for all stock-based payments to employees and non-employees, including grants of stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs"), to be recognized in the consolidated financial statements based on their respective grant date fair values. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The RSUs and RSAs, are valued based on the fair value of the Company’s common stock on the date of grant. The Company expenses stock-based compensation related to stock options, RSUs and RSAs over the requisite service period. All stock-based compensation costs are recorded in cost of products sold, research and development expense or SG&A expense in the condensed consolidated statements of operations and comprehensive loss based upon the respective employee’s or non-employee’s roles within the Company. Forfeitures are recorded as they occur. See Note 15—Stock-Based Compensation for additional details.
Income Taxes
Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse, and net operating loss (“NOL”) carryforwards and research and development tax credit carryforwards. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.
15


Warrant Liability
The Company accounts for certain common stock warrants outstanding as a liability at fair value, determined using the Black-Scholes option pricing model, on the consolidated balance sheets in accordance with ASC 815, Derivatives and Hedging (“ASC 815”). The liability is subject to re-measurement at each reporting period and any change in fair value is recognized in the condensed consolidated statements of operations and comprehensive loss. See Note 13—Warrants for additional details.
Business Combinations
The Company accounts for business acquisitions using the acquisition method of accounting based on ASC 805, Business Combinations (“ASC 805”), which requires recognition and measurement of all identifiable assets acquired and liabilities assumed at their fair value as of the date control is obtained. The Company determines the fair value of assets acquired and liabilities assumed based upon its best estimates of the acquisition-date fair value of assets acquired and liabilities assumed in the acquisition. Goodwill is calculated as the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired.
Recently Adopted Accounting Pronouncements
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326) ("ASU 2016-13"). ASU 2016-13 sets forth a “current expected credit loss” model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost, available-for-sale debt securities and applies to certain off-balance sheet credit exposures. ASU 2016-13 is effective for smaller reporting companies in 2023. The Company adopted the guidance in the first quarter of 2023 with no material impact on the condensed consolidated financial statements.
Note 3—Sale of Business
On June 30, 2022, the Company completed the First Closing in accordance with the Asset Purchase Agreement with Medtronic, pursuant to which the Company agreed to sell to Medtronic certain transseptal access and sheath assets which make up the Company's left-heart access portfolio (and which comprised the Rhythm Xience product line acquired as part of the Rhythm Xience acquisition). The assets transferred to Medtronic upon the First Closing (the “Assets”) include patents, trademarks, patent and trademark applications, know-how, copyrights, prototypes and other intellectual property owned or licensed by the Company, business records and documents (including regulatory and clinical materials) and manufacturing equipment related to the AcQCross® line of sheath-compatible septal crossing devices, AcQGuide® MINI integrated crossing device and sheath, AcQGuide® FLEX Steerable Introducer with integrated transseptal dilator and needle, and AcQGuide® VUE steerable sheaths (the “Products”).

Pursuant to the Asset Purchase Agreement, Medtronic paid $50.0 million at the First Closing, of which $4.0 million was paid into an indemnity escrow account for a period of 18 months following the First Closing to secure indemnification obligations of the Company under the Asset Purchase Agreement, which the Company has recorded as restricted cash on its condensed consolidated balance sheets.
The Company is also eligible to receive the following contingent cash consideration pursuant to the Asset Purchase Agreement:

(i)    $20.0 million upon the Company’s completion, to the reasonable satisfaction of Medtronic, of certain conditions set forth in the Asset Purchase Agreement relating to the Company becoming a qualified supplier of Medtronic for the Products, including demonstration of ISO 14971:2019 compliance, completion of certain test method validations and compliance with certain other reporting requirements (the “OEM Earnout”);
(ii)    $17.0 million upon the earlier of (A) the Second Closing (as defined below) or (B) the Company’s initial submission for CE Mark certification of the Products under the European Union Medical Devices Regulation, to the reasonable satisfaction of a third-party regulatory consultant, subject to certain other conditions as set forth in the Asset Purchase Agreement (the “Transfer Earnout”); and
(iii)    amounts equal to 100%, 75%, 50% and 50%, respectively, of quarterly Net Sales (as defined in the Asset Purchase Agreement) from sales of the Products achieved by Medtronic over each year of a four-year period beginning on the first full quarter after Medtronic’s first commercial sale of a Product and achievement of the OEM Earnout.

16
The $20.0 million OEM Earnout was achieved in October 2022 and payment was received in November 2022, of which $1.6 million is held in escrow and recorded as restricted cash on the condensed consolidated balance sheets. The $17.0 million Transfer Earnout was achieved in December 2022 and payment was received in January 2023, of which $1.4 million is held in escrow and recorded as restricted cash on the condensed consolidated balance sheets. During the three months ended March 31, 2023, $1.2 million was earned under item (iii) and recorded as a receivable on the condensed consolidated balance sheet as of March 31, 2023.

With the achievement of the OEM Earnout Conditions (as defined in the Asset Purchase Agreement) and upon notice from Medtronic, Medtronic became the Company's exclusive distributor of the Products under the Distribution Agreement.

The Company recorded a net gain of $79.5 million during the year ended December 31, 2022 related to the sale of business to Medtronic, calculated as the difference between the non-contingent consideration received, less direct transaction costs and the net carrying amount of the assets sold.

The Company recorded the following amounts for the three months ended March 31, 2023, resulting in a net gain of $1.2 million related to the sale of business to Medtronic, calculated as the difference between the non-contingent consideration earned, less direct transaction costs (in thousands):

Three Months Ended March 31, 2023
(unaudited)
Percentage of Product Net Sales Earnout accrued as of March 31, 2023$1,244 
Transaction costs(37)
          Gain on sale of business, net$1,207 

The net gain on sale will be adjusted in future periods by the contingent consideration, based on the achievement of the predetermined milestones mentioned above. The sale was accounted for as a derecognition of a group of assets that is a business pursuant to ASC 810 - Consolidation, with the resulting gain classified as operating income within loss from operations on the condensed consolidated statements of operations and comprehensive loss. The sale does not represent a strategic shift having a major effect on the Company's operations and financial results and, consequently, does not qualify as a discontinued operation.
Note 4—Marketable Securities
Marketable securities consisted of the following as of March 31, 2023 and December 31, 2022 (in thousands):
March 31, 2023 (unaudited)
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Available-for-sale securities - short-term:
U.S. treasury securities$21,809 $5 $— $21,814 
Commercial paper21,806 — — 21,806 
Yankee debt securities3,220 — (1)3,219 
Total available-for-sale securities - short-term46,835 5 (1)46,839 
     Total available-for-sale securities$46,835 $5 $(1)$46,839 

17
December 31, 2022
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Available-for-sale securities - short-term:
U.S. treasury securities$26,906 $3 $(12)$26,897 
Commercial paper3,200 2 — 3,202 
Yankee debt securities14,764 — — 14,764 
Total available-for-sale securities - short-term44,870 5 (12)44,863 
     Total available-for-sale securities$44,870 $5 $(12)$44,863 
As of March 31, 2023, the Company’s available-for-sale securities classified as short-term of $46.8 million mature in 1 year or less and there were none held long-term. As of December 31, 2022, the Company’s available-for-sale securities classified as short-term of $44.9 million mature in 1 year or less and there were none held long-term.
Note 5—Inventory
Inventory as of March 31, 2023 and December 31, 2022 consisted of the following (in thousands):
March 31,
2023		December 31,
2022
(unaudited)
Raw materials$10,253 $9,179 
Work in process1,843 2,025 
Finished goods2,842 2,123 
Total inventory$14,938 $13,327 
Note 6—Lessor Sales-Type Leases
The Company recognizes revenue and costs, as well as a lease receivable, at the commencement of embedded sales-type leases within its deferred equipment agreements. There was no lease revenue related to sales-type leases for both the three months ended March 31, 2023 and 2022. Costs related to embedded leases within the Company’s deferred equipment agreements are included in cost of products sold in the condensed consolidated statements of operations and comprehensive loss.
As of March 31, 2023 and December 31, 2022, a balance of $0.6 million for both periods for short-term leases receivable is recorded in prepaid expenses and other current assets on the condensed consolidated balance sheets, and a balance of $0.4 million and $0.5 million, respectively, for long-term leases receivable is recorded in other assets related to sales-type leases.
The following table is an estimation of maturities of customer sales-type lease receivables for each of the following years as of March 31, 2023 (in thousands):
Total Maturities
Nine months ending December 31, 2023$527 
Year ending December 31, 2024393 
Year ending December 31, 2025133 
     Total maturities of customer sales-type leases$1,053 
Note 7—Property and Equipment, Net
The Company’s property and equipment, net, consisted of the following as of March 31, 2023 and December 31, 2022 (in thousands):
18
March 31,
2023		December 31,
2022
(unaudited) 
Medical diagnostic equipment$15,042 $14,826 
Furniture and fixtures400 432 
Office equipment1,556 1,556 
Laboratory equipment and software5,226 5,148 
Leasehold improvements608 580 
Construction in process2,008 2,166 
Total property and equipment24,840 24,708 
Less: accumulated depreciation(16,695)(15,487)
Property and equipment, net$8,145 $9,221 

Property and equipment includes certain medical diagnostic equipment and AcQMap Systems located at customer premises. The Company retains ownership of the equipment and has the right to remove the equipment if it is not being used according to expectations. The Company records the cost of equipment to cost of sales on the condensed consolidated statements of operations and comprehensive loss when it is subsequently sold or the Company enters into a sales-type lease agreement. See Note 6 - Lessor Sales-Type Leases for additional details.
Depreciation expense was $1.3 million and $1.6 million for the three months ended March 31, 2023 and 2022, respectively.
Note 8—Intangible Assets
The following table presents intangible assets activity for the three months ended March 31, 2023 (in thousands):
Intangible
Assets
Balance, December 31, 2022$1,583 
Amortization expense(50)
Balance, March 31, 2023 (unaudited)$1,533 

Intangible Assets
The tables below present the details of intangible assets as of March 31, 2023 and December 31, 2022 (dollars in thousands):
March 31, 2023Estimated
Useful
Life
(in years)		Weighted
Average
Remaining
Life
(in years)		Intangible
Assets		Accumulated
Amortization		Balance
(unaudited)
Licensed intangibles10.07.7$2,000 $(467)$1,533 
     Total intangible assets$2,000 $(467)$1,533 
December 31, 2022Estimated
Useful
Life
(in years)		Weighted
Average
Remaining
Life
(in years)		Intangible
Assets		Accumulated
Amortization		Balance
Licensed intangibles10.07.92,000 (417)1,583 
     Total intangible assets$2,000 Rx$(417)$1,583 

The Company recorded amortization expense related to the above intangible assets of $0.1 million and $0.2 million for the three months ended March 31, 2023 and 2022, respectively.
19
The following table presents the future amortization expense associated with amortizable intangible assets as of March 31, 2023 (in thousands):
Total
Amortization
Nine months ending December 31, 2023$150 
Year ending December 31, 2024200 
Year ending December 31, 2025200 
Year ending December 31, 2026200 
Year ending December 31, 2027200 
Thereafter583 
     Total future amortization$1,533 

Note 9—Accrued Liabilities
Accrued liabilities consisted of the following as of March 31, 2023 and December 31, 2022 (in thousands):
March 31,
2023		December 31,
2022
(unaudited)
Compensation and related expenses$4,988 $6,919 
Professional fees169 126 
Deferred revenue297 326 
Sales and use tax724 639 
Clinical studies252 390 
Clinician Council payable